# US 10,865,435 B2 · Method of screening antibacterial compounds as inhibitor of Mfd

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,865,435 B2
- Document ID: US10865435B2
- Status: Granted
- Kind: B2
- Application number: 16/094,864
- Filed: 2017-05-03
- Published: 2019-11-14
- Granted: 2020-12-15
- Earliest claimed: 2016-05-03
- Assignees: Institut National De Recherche Pour L'agriculture; Centre National De La Recherche Scientifique; Universite De Strasbourg
- Applicants: Institut National De La Recherche Agronomique; Centre National De La Recherche Scientifique; Universite De Strasbourg
- Inventors: Nalini Rama Rao; Didier Rognan; Didier Lereclus
- Web page: https://patentgrep.com/patent/US10865435B2

## CPC

- C12Q 1/18: Testing for antimicrobial activity of a material
- G16B 35/00: ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B 35/20: Screening of libraries
- G16C 20/60: In silico combinatorial chemistry
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

Embodiments of the present disclosure relate to methods of screening and optionally designing compounds as inhibitors of Mfd (Mutation Frequency Decline), such compounds being useful for the treatment of bacterial infections. Embodiments of the methods include culturing pathogenic bacteria expressing functional Mfd with various concentrations of 1 mM or less, incubating the cultures with and without nitric oxide stress conditions, evaluating bacterial survival in each of the cultures, and calculating the concentration of the molecule required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the untreated cultures and cultures following nitric oxide stress.

## Claims

### Claim 1

An in vitro method of screening an antibacterial molecule that inhibits mutation frequency decline (Mfd peptide) activity comprising the steps of:
(a) preparing several pairs of cultures of a pathogenic bacteria expressing a functional Mfd in culture media containing different concentrations of said molecule to be tested; wherein said concentrations of molecule to be tested are less than or equal to 1 mM;
(b) incubating one of each pair of cultures in nitric oxide stress conditions obtained by addition of NO donors in said culture media, leaving the other culture of each pair untreated;
(c) evaluating the bacterial survival in each of the cultures;
(d) calculating the concentration of the molecule to be tested required to decrease by 50% the survival rate of the bacteria (IC50) by comparing the cfu of the culture with the molecule to be tested in two conditions: untreated and following nitric oxide stress;
(d2) selecting the molecule showing an IC50 less or equal to 200 μM;
(e) incubating the Mfd peptide with the molecule identified as a Mfd inhibitor;
(f) determining whether or not the ATPase activity of Mfd is reduced relative to the activity of a Mfd that has not been contacted with said molecule.

### Claim 2 (depends on 1)

The in vitro method of screening an antibacterial molecule according to claim 1, wherein said pathogenic bacteria is a Gram-positive or a Gram-negative human pathogenic bacteria.

### Claim 3 (depends on 1)

The in vitro method of screening an antibacterial molecule according to claim 1, wherein said nitric oxide stress is artificially produced in vitro by addition of NO donors at concentration between 0.1 and 2 mM.

### Claim 4 (depends on 1)

The in vitro method of screening an antibacterial molecule according to claim 1, wherein the evaluation of the bacterial survival of step (c) is performed by plating on agar plates the harvested bacteria obtained after incubation of step (b), by flow cytometry, or by using a live and dead kit.

### Claim 5 (depends on 1)

The in vitro method of screening an antibacterial molecule that inhibits the Mfd activity according to claim 1, comprising additional steps prior to said step (a) consisting of in silico screening for potential Mfd inhibitors including:
(a1) generating using a homology modelling program to generate a three-dimensional model of the ATP-binding domain of Mfd using three-dimensional atomic coordinates of the ATP-binding domain of Mfd;
(a2) screening a library of physically-available small molecules for compounds predicted to occupy the ATP-binding site by a docking computational method, a pharmacophore search computational method, a de novo design method, or an active site comparison method; and
(a3) selecting virtual hits for experimental validation according to a docking score, a pharmacophore fitness value, a predicted binding free energy, or an active site similarity score.

### Claim 6 (depends on 2)

The in vitro method of screening an antibacterial molecule according to claim 2, wherein the human pathogenic bacteria is selected from Bacillus cereus group members, Shigella, Salmonella, Clostridium, Staphylococcus, Klebsiella, E. coli, Neisseria, Yersinia, Listeria, Streptococcus, Mycobacterium, Clamydia and Helicobacter species.